Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program

Urology

Volumn 81, Issue 1, 2013, Pages 143-149

  Van Den Eertwegh, Alfonsus J M ^a,b   Karakiewicz, Pierre ^a   Bavbek, Sevil ^a   Rha, Sun Young ^a   Bracarda, Sergio ^a   Bahl, Amit ^a   Ou, Yen Chuan ^a   Kim, Dennis ^a   Panneerselvam, Ashok ^a   Anak, Oezlem ^a   Grünwald, Viktor ^a  

^a not available

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS;

ADULT; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HEALTH PROGRAM; HUMAN; HYPERGLYCEMIA; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84871940229     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.09.019     Document Type: Article

References (18)

1. M.H. Voss, A.M. Molina, and R.J. Motzer mTOR inhibitors in advanced renal cell carcinoma Hematol Oncol Clin North Am 25 2011 835 852
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Kidney Cancer (Version 2.2012). http://www.nccn.org. Accessed March 16, 2012.
3. B. Escudier, T. Eisen, and C. Porta Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 suppl 7 2012 vii65 vii71
4. B. Ljungberg, N.C. Cowan, and D.C. Hanbury EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 2010 398 406
5. T.M. de Reijke, J. Bellmunt, and H. van Poppel EORTC-GU group expert opinion on metastatic renal cell cancer Eur J Cancer 45 2009 765 773
6. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
7. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
8. E. Calvo, B. Escudier, and R.J. Motzer Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study Eur J Cancer 48 2012 333 339
9. V. Grunwald, P.I. Karakiewics, and S.E. Bavbek An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy Eur J Cancer 48 2012 324 332
10. T.K. Choueiri, and M.B. Atkins Sunitinib in RCC - expanded access equals expanded benefit? Clin Oncol 6 2009 679 680
11. W.M. Stadler, R.A. Figlin, and D.F. McDermott Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Cancer 116 2010 1272 1280
12. M.E. Gore, C. Szczylik, and C. Porta Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757 763
13. J. Bellmunt, T. Eisen, and C. Szczylik A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options BJU Int 107 2010 1190 1199
14. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
15. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Version 3.0 2006 National Institutes of Health, U.S. Department of Health and Human Services Rockville, MD
16. T.E. Hutson, J. Bellmunt, and C. Porta Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET Eur J Cancer 46 2010 2432 2440
17. S. Oudard, and R.T. Elaidi Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit [e-pub ahead of print] Cancer Treat Rev 38 2012 981 987 http://dx.doi.org/10.1016/j. ctrv.2011.12.009 Accessed September 16, 2012
18. Bono P, Kim D, Panneerselvam A, et al. Hyperglycemia and hypercholesterolaemia and associated outcomes of patients with metastatic renal cell carcinoma treated with everolimus in the expanded-access programme REACT. Presented at the 2011 European Multidisciplinary Cancer Congress; 23-27 September 2011; Stockholm, Sweden. Abstract 7148.